<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: This study evaluated the effect of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> versus <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> on arterial stiffness, blood pressure, <z:chebi fb="23" ids="18059">lipid</z:chebi> profile, <z:mp ids='MP_0003674'>oxidative stress</z:mp>, and high-sensitivity C-reactive protein (hsCRP) in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>SUBJECTS AND METHODS: Forty <z:mp ids='MP_0002055'>diabetes</z:mp> patients, inadequately controlled on <z:chebi fb="0" ids="6801">metformin</z:chebi>, were randomly assigned to either <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> (100 mg/day) or <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> (5 mg/day) for 3 months </plain></SENT>
<SENT sid="2" pm="."><plain>Following a 1-month washout period, a crossover switch from <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> to <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> and vice versa was performed for an additional 3 months </plain></SENT>
<SENT sid="3" pm="."><plain>Arterial stiffness, 24-h ambulatory blood pressure monitoring, <z:chebi fb="23" ids="18059">lipids</z:chebi>, hsCRP, glycated <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, fasting <z:chebi fb="105" ids="17234">glucose</z:chebi>, STAT-8-isoprostane (a measure of <z:mp ids='MP_0003674'>oxidative stress</z:mp>), body mass index (BMI), and waist circumference were measured at baseline and at 3 months with each of the study drugs </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Thirty-four patients completed the study </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="5441">Glibenclamide</z:chebi> had a better <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering effect than <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>, but this was associated with more hypoglycemic events </plain></SENT>
<SENT sid="6" pm="."><plain>BMI increased following <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> treatment, whereas <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> proved weight-neutral </plain></SENT>
<SENT sid="7" pm="."><plain>Mean BMI gain was +0.5±1.0 kg/m(2) for <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> versus -0.01±0.9 kg/m(2) for <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> (P&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="17855">Triglyceride</z:chebi> levels significantly dropped following <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>, although they remained unaltered after <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> treatment </plain></SENT>
<SENT sid="9" pm="."><plain>Mean <z:chebi fb="0" ids="17855">triglyceride</z:chebi> decrease was -18.4±45 mg/mL after <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> but -0.2±57 mg/dL following <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> treatment (P=0.018) </plain></SENT>
<SENT sid="10" pm="."><plain>There was no change in <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi>, <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi>, arterial stiffness, blood pressure monitoring, hsCRP, or STAT-8-isoprostane with each of the study drugs </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="40237">Sitagliptin</z:chebi>, but not <z:chebi fb="0" ids="5441">glibenclamide</z:chebi>, demonstrated a significant beneficial effect on BMI and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels </plain></SENT>
<SENT sid="12" pm="."><plain>However, arterial stiffness, blood pressure, <z:mp ids='MP_0003674'>oxidative stress</z:mp>, and inflammatory status were not significantly affected by adding <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> or <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> to <z:chebi fb="0" ids="6801">metformin</z:chebi>-treated type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients </plain></SENT>
</text></document>